Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia

NCT01566890 is registered in ClinicalTrials.gov with Versiti Blood Health as lead sponsor.

NCT NCT01566890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01566890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell Anemia
Lead sponsor
Versiti Blood Health
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2012
Completion date
November 16, 2020
Enrollment
91 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia, sickle cell disease